Table 2.
Effectiveness of rotavirus vaccine against rotavirus disease by severity, Bolivia
| Group | One dose vaccinees* | Two dose vaccinees* | |||||
|---|---|---|---|---|---|---|---|
| No/total (%) | Vaccine effectiveness, % (95% CI) | No/total (%) | Vaccine effectiveness, % (95% CI) | ||||
| Crude | Adjusted | Crude | Adjusted | ||||
| Rotavirus disease requiring hospital admission | |||||||
| Cases | 100/192 (52) | — | — | 208/300 (69) | — | — | |
| Non-diarrhea controls† | 226/343 (66) | 57 (35 to 71) | 56 (32 to 72) | 857/974 (88) | 80 (70 to 86) | 77 (65 to 84) | |
| Test negative controls‡ | 131/208 (63) | 39 (8 to 60) | 36 (0 to 59) | 510/587 (87) | 70 (56 to 79) | 69 (54 to 79) | |
| Severe rotavirus disease (Vesikari severity score ≥11) | |||||||
| Cases | 92/177 (52) | — | — | 196/281 (70) | — | — | |
| Non-diarrhea controls† | 207/316 (66) | 55 (30 to 70) | 54 (28 to 70) | 803/912 (88) | 79 (68 to 85) | 76 (64 to 84) | |
| Test negative controls‡ | 131/208 (63) | 42 (11 to 62) | 34 (−5 to 69) | 510/587 (87) | 70 (55 to 79) | 69 (53 to 79) | |
| Very severe rotavirus disease (Vesikari score ≥15) | |||||||
| Cases | 53/91 (58) | — | — | 100/138 (72) | — | — | |
| Non-diarrhea controls† | 112/166 (67) | 40 (−1 to 68) | 40 (−9 to 66) | 407/461 (88) | 77 (60 to 87) | 74 (54 to 85) | |
| Test negative controls‡ | 131/208 (63) | 24 (−27 to 55) | 6 (−63 to 78) | 510/587 (87) | 66 (44 to 79) | 62 (37 to 88) | |
*Cases and controls were considered vaccinated with respective number of doses (one or two) if most recent dose was administered ≥14 days before date of case’s hospital visit.
†Because non-diarrhea controls were matched on age and hospital, conditional logistic regression was used to compute odds ratio for vaccination (one or two doses) versus no vaccination; crude vaccine effectiveness includes only vaccination in model; adjusted vaccine effectiveness for model with hospital admission includes sex, number of children and rooms in home, and computer; model for Vesikari ≥11 includes sex and number of children and rooms in home; model for Vesikari ≥15 includes sex and number of rooms in home.
‡Unconditional logistic regression was used to compute odds ratio for vaccination (one or two doses) versus no vaccination among cases and test negative controls; crude vaccine effectiveness adjusts only for age in months, month/year of birth, and hospital; adjusted vaccine effectiveness for model with hospital admission includes age in months, month/year of birth, hospital, sex, number of children and rooms in home, and computer; model for Vesikari ≥11 includes age in months, month/year of birth, hospital, sex, and number of children and rooms in home; model for Vesikari ≥15 includes age in months, month/year of birth, hospital, sex, and number of rooms in home.